These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37354015)

  • 21. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M
    Zhang K; Wang T; Li M; Liu M; Tang H; Wang L; Ye K; Yang J; Jiang S; Xiao Y; Xie Y; Lu M; Zhang X
    Eur J Med Chem; 2023 Sep; 257():115487. PubMed ID: 37257212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
    Deodato D; Asad N; Dore TM
    Bioorg Med Chem Lett; 2022 Sep; 72():128867. PubMed ID: 35760254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity.
    Wang R; Chen X; Li H; Chen X; Sun D; Yu D; Lu J; Xie Y; Zhang Q; Xu J; Zhang W; Chen H; Liu S; Chen L
    Int J Biol Macromol; 2024 Feb; 257(Pt 2):128623. PubMed ID: 38070810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors.
    Guo N; Huang C; Qiao J; Li Y; Wang Y; Xia A; Zhang G; Fang Z; You J; Li L
    Bioorg Med Chem Lett; 2023 Apr; 86():129238. PubMed ID: 36924946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
    Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
    Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
    Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
    Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular interactions and inhibition of the SARS-CoV-2 main protease by a thiadiazolidinone derivative.
    Andrzejczyk J; Jovic K; Brown LM; Pascetta VG; Varga K; Vashisth H
    Proteins; 2022 Nov; 90(11):1896-1907. PubMed ID: 35567429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure of M
    Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
    Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease.
    Wang F; Zeng R; Qiao J; Xia A; Li Y; Li F; Wu Y; Liu Y; Zhao X; Lei J; Yang S
    Bioorg Med Chem Lett; 2023 Aug; 92():129407. PubMed ID: 37437852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].
    Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB
    Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
    La Monica G; Bono A; Lauria A; Martorana A
    J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
    Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.
    Sasi VM; Ullrich S; Ton J; Fry SE; Johansen-Leete J; Payne RJ; Nitsche C; Jackson CJ
    Biochemistry; 2022 Nov; 61(22):2495-2505. PubMed ID: 36326185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (M
    Elgohary AM; Elfiky AA; Pereira F; Abd El-Aziz TM; Sobeh M; Arafa RK; El-Demerdash A
    Comput Biol Med; 2022 Aug; 147():105738. PubMed ID: 35777088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
    Chakraborti S; Bheemireddy S; Srinivasan N
    Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2.
    Joshi RP; Schultz KJ; Wilson JW; Kruel A; Varikoti RA; Kombala CJ; Kneller DW; Galanie S; Phillips G; Zhang Q; Coates L; Parvathareddy J; Surendranathan S; Kong Y; Clyde A; Ramanathan A; Jonsson CB; Brandvold KR; Zhou M; Head MS; Kovalevsky A; Kumar N
    J Chem Inf Model; 2023 Mar; 63(5):1438-1453. PubMed ID: 36808989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.